BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 18, 2026
Breaking News: Tracking hantavirus across the globeBreaking News: WHO declares Ebola outbreak a public health emergency of international concernBreaking News: WHO declares Ebola outbreak a public health emergency of international concern
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

MRI scan of a fixed cerebral hemisphere from a person with multiple sclerosis
Neurology/Psychiatric

First GWAS for MS severity turns up first brain-related SNP

June 29, 2023
By Anette Breindl
Multiple sclerosis (MS) is and remains “a problem in the immune system” Stephen Sawcer told BioWorld. As in other autoimmune diseases, a faulty immune system attacks otherwise healthy tissues that it should be leaving alone. In the case of MS, the tissue in question is oligodendrocytes. And a study published online in Nature on June 28, 2023, suggests that while MS’ beginnings are autoimmune, the path it takes in an individual patient is determined in part by how well the brain can cope with the autoimmune attack.
Read More
Neurology/Psychiatric

Astrazeneca divulges new RIPK1 inhibitors for neurological disorders

June 27, 2023
Astrazeneca AB has synthesized pyraolo-and triazolo-azinone compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of neurological disorders.
Read More
Side view of head and neck, highlighting the throat
Neurology/Psychiatric

Benitec’s BB-301 cleared to enter clinic in US for oculopharyngeal muscular dystrophy-related dysphagia

June 27, 2023
Benitec Biopharma Inc. has received FDA clearance of its IND application for BB-301, its silence and replace gene therapy for the treatment of oculopharyngeal muscular dystrophy (OPMD)-related dysphagia.
Read More
Neurology/Psychiatric

Convelo and Genentech patent new EBP inhibitors

June 26, 2023
Convelo Therapeutics Inc. and Genentech Inc. have disclosed 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.
Read More
Neurology/Psychiatric

French researchers describe new MAPT aggregation inhibitors for Alzheimer’s disease

June 23, 2023
Researchers at Centre National de la Recherche Scientifique, Université De Picardie Jules Verne and Université Paris-Est Créteil Val de Marne (UPEC) have identified lipid anionic oligosaccharides acting as microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Read More
Neurology/Psychiatric

University of Western Australia patents new MDMA analogues for modulating SERT, DAT and/or NET activity

June 23, 2023
University of Western Australia has disclosed 3,4-methylenedioxymethamphetamine (MDMA) analogues acting as dopamine transporter (DAT) and/or norepinephrine transporter (NET) and/or serotonin transporter (SERT) modulators reported to be useful for the treatment of neurological and psychiatric disorders.
Read More
Neurology/Psychiatric

Alchemab Therapeutics presents newly discovered CD33-targeting antibody for Alzheimer’s disease

June 23, 2023
Alchemab Therapeutics Ltd. has presented ATLX-1088, its newly discovered preclinical Alzheimer’s candidate, and provided early data.
Read More
Neurology/Psychiatric

Remix Therapeutics patents new RNA splicing modulators

June 22, 2023
Remix Therapeutics has disclosed compounds acting as RNA splicing modulators reported to be useful for the treatment of cancer and Huntington’s disease.
Read More
Pediatric brain illustration
Biomarkers

INDYGON syndrome, a novel spliceosomopathy caused by biallelic variants in SART3

June 22, 2023
Researchers from Murdoch Children’s Research Institute presented data from a study that linked recessive variants in the SART3 gene with a novel neurodevelopmental syndrome.
Read More
Neurology/Psychiatric

New Cav2.3 antagonists described in Lario Therapeutics patents

June 21, 2023
Several Lario Therapeutics Ltd. patents describe new voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) antagonists reported to be useful for the treatment of neurodegeneration, epilepsy, Parkinson’s disease, cerebral vasospasm, pain, CDKL5 deficiency, endocrine and neurodevelopmental disorders, among others.
Read More
Previous 1 2 … 174 175 176 177 178 179 180 181 182 … 2803 2804 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • DNA and genome editing illustration

    ASGCT 2026: Directed evolution in gene therapy

    BioWorld
    Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
  • Doctor with brain illustration, businessman with dollar sign illustration

    Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal

    BioWorld
    Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing